TY  - CONF

T1  - Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations

JO  - Journal of Clinical Oncology

UR  - http://dx.doi.org/10.1200/jco.23.00943

PY  - 2024/01/12

AU  - Russell NH

AU  - Wilhelm-Benartzi C

AU  - Othman J

AU  - Dillon R

AU  - Knapper S

AU  - Batten LM

AU  - Canham J

AU  - Hinson EL

AU  - Betteridge S

AU  - Overgaard UM

AU  - Gilkes A et al

ED  - 

DO  - DOI: 10.1200/jco.23.00943

PB  - American Society of Clinical Oncology (ASCO)

VL  - 42

IS  - 10

SP  - 1158

EP  - 1168

Y2  - 2024/12/28

ER  -